US-based medical device company BioVentrix has reported the first clinical application of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System in The Netherlands.

Designed for the less invasive ventricular enhancement (LIVE) procedure, the Revivent TC System serves as an alternative to conventional surgical ventricular restoration (SVR), by enabling a closed-chest approach.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Revivent TC System is placed without sternotomy or ventriculotomy, thereby eliminating the need for cardiopulmonary bypass.

"We achieved a sizeable reduction in the patient's left ventricular volume and he will see significant improvement in his symptoms."

Its proprietary transcatheter delivery system enables volume reduction of the left ventricle (LV) through placement of anchors designed to exclude scarred myocardial tissue from the left ventricle while also restoring its more natural conical shape.

The Revivent TC System uses a hybrid endovascular technique performed in the hybrid cath lab which allows treatment of fragile patient population by eliminating the risks of open surgical intervention.

See Also:

During the procedure conducted in The Netherlands, the device was successfully implanted using four micro-anchor pairs in a 56-year-old male patient suffering from ischemic heart failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The procedure reshaped the left ventricle and decreased the left ventricular end systolic volume index (LVESVI).

St Antonius Hospital in Nieuwegein, The Netherlands interventional cardiologist Dr Pierfrancesco Agostoni said: "We achieved a sizeable reduction in the patient's left ventricular volume and he will see significant improvement in his symptoms.

“The LIVE procedure is clearly less invasive and provides an important sense of control when operating on the beating heart.”